Why New Part B Drug Model Could Hit Oncology the Hardest
Published on Mon Mar 21, 2016
Could prior studies have already proven opposite results? Oncologist organizations have been especially vocal in their dissent concerning the recent proposed rule to makeover the way Medicare Part B pays for prescription drugs provided in physician offices and hospital outpatient departments. The reason, in part, is due to the high prevalence of oncology-related and expensive drugs paid under Part B. [...]